Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study

This article was originally published in The Pink Sheet Daily

Executive Summary

A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.

You may also be interested in...



GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome

GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors

GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome

GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors

Pfizer's McKinnell Cancels National Press Club Speech

Exec was expected to discuss health care reform, and was likely to have been asked about cardiovascular safety of Celebrex and Bextra. McKinnell canceled the speech due to the flu, which he caught in Asia while assessing Pfizer's tsunami relief efforts.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel